Back to results

CompletedPhase 2

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NCT00566202

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Little Rock, Arkansas, United States

+25 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2007-12
Enrollment: 67 participants
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Purpose: treatment

Locations (26)

Little Rock, Arkansas, United States
Beverly Hills, California, United States
Glendale, California, United States
San Diego, California, United States
Bradenton, Florida, United States
Maitland, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Eagle, Idaho, United States
Chicago, Illinois, United States
Prairie Village, Kansas, United States
Topeka, Kansas, United States
Baton Rouge, Louisiana, United States
Shreveport, Louisiana, United States
Nutley, New Jersey, United States
Brooklyn, New York, United States
Cedarhurst, New York, United States
Fresh Meadows, New York, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Norristown, Pennsylvania, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Irving, Texas, United States
Richmond, Virginia, United States